It's a drug that provides short-term benefits for heart transplant and heart failure patients by increasing heart contractility, but in the long-term it causes arrhythmia. It inhibits type 3 phosphodiesterases (PDE3s). Recent work suggests that its target in heart is probably the A isoform (PDE3A) (which is not that surprising given that it's PDE3A that's mostly expressed in heart muscle).
No comments:
Post a Comment